EA202190672A1 - Инъекционный антибиотический состав с замедленным высвобождением - Google Patents

Инъекционный антибиотический состав с замедленным высвобождением

Info

Publication number
EA202190672A1
EA202190672A1 EA202190672A EA202190672A EA202190672A1 EA 202190672 A1 EA202190672 A1 EA 202190672A1 EA 202190672 A EA202190672 A EA 202190672A EA 202190672 A EA202190672 A EA 202190672A EA 202190672 A1 EA202190672 A1 EA 202190672A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
slow release
addition
gel
release antibiotic
Prior art date
Application number
EA202190672A
Other languages
English (en)
Inventor
Михаэль Фридман
Давид Кирмайер
Захар Нудельман
Амнон Хоффман
Эран Лави
Аяла Бар-Хай
Ирит Гати
Original Assignee
Иссум Рисерч Дивелопмент Компани Оф Те Хибру Юниверсити Оф Джерусалем Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иссум Рисерч Дивелопмент Компани Оф Те Хибру Юниверсити Оф Джерусалем Лтд. filed Critical Иссум Рисерч Дивелопмент Компани Оф Те Хибру Юниверсити Оф Джерусалем Лтд.
Publication of EA202190672A1 publication Critical patent/EA202190672A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В настоящем документе обеспечены композиции инъекционных антибиотиков для ветеринарного применения. Композиции характеризуются образованием геля при физиологической температуре животного, причем указанный гель характеризуется стабильным и повторяемым профилем высвобождения антибиотика. Композиции содержат высокую нагрузку лекарственного средства в растворах полоксамера с добавлением сорастворителя и предпочтительно с добавлением производного целлюлозы, по меньшей мере частично растворимого в органических растворителях. Также обеспечены способы лечения ветеринарных инфекций.
EA202190672A 2018-09-06 2019-09-05 Инъекционный антибиотический состав с замедленным высвобождением EA202190672A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862727574P 2018-09-06 2018-09-06
PCT/IL2019/050998 WO2020049570A1 (en) 2018-09-06 2019-09-05 Sustained-release injectable antibiotical formulation

Publications (1)

Publication Number Publication Date
EA202190672A1 true EA202190672A1 (ru) 2021-07-01

Family

ID=68072920

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190672A EA202190672A1 (ru) 2018-09-06 2019-09-05 Инъекционный антибиотический состав с замедленным высвобождением

Country Status (14)

Country Link
US (1) US20210315803A1 (ru)
EP (1) EP3846781A1 (ru)
JP (1) JP2021536485A (ru)
KR (1) KR20210099553A (ru)
CN (1) CN113412109A (ru)
BR (1) BR112021004192A2 (ru)
CA (1) CA3111385A1 (ru)
CL (1) CL2021000536A1 (ru)
CO (1) CO2021004131A2 (ru)
EA (1) EA202190672A1 (ru)
MX (1) MX2021002492A (ru)
PE (1) PE20211334A1 (ru)
PH (1) PH12021550477A1 (ru)
WO (1) WO2020049570A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114306211B (zh) * 2021-12-29 2023-12-22 中国药科大学 一种甘草酸超分子自组装温敏互穿网络凝胶及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740421A (en) 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
US5035891A (en) 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
DE69636626T2 (de) 1995-07-28 2007-08-30 Genzyme Corp., Cambridge Biologische abbaubare multiblokhydrogene und ihre verwendung wie trägerstoffe fur kontrollierte freisetzung pharmakologisch activen werstoffe und gewebekontaktmaterialen
US6316011B1 (en) 1998-08-04 2001-11-13 Madash, Llc End modified thermal responsive hydrogels
JP4644397B2 (ja) * 2001-09-05 2011-03-02 信越化学工業株式会社 難溶性薬物を含む医薬用固形製剤の製造方法
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
US6790867B2 (en) * 2002-05-20 2004-09-14 Schering-Plough Animal Health Corporation Compositions and method for treating infection in cattle and swine
US20040247672A1 (en) 2003-05-16 2004-12-09 Alkermes Controlled Therapeutics, Inc. Injectable sustained release compositions
NZ555774A (en) * 2004-12-21 2010-09-30 Intervet Int Bv Injectable veterinary composition comprising florfenicol, a pyrrolidone solvent and a cosolvent selected from diethyleneglycol monoethyl ether and / or tetrahydrofurfuryl alcohol polyethylene glycol ether
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
US8614315B2 (en) * 2009-12-25 2013-12-24 Mahmut Bilgic Cefdinir and cefixime formulations and uses thereof
AU2011280985C1 (en) * 2010-07-22 2016-04-21 Reven Pharmaceuticals, Inc. Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution
US11052043B2 (en) * 2011-03-28 2021-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Sustained-release injectable formulation
CN103202802A (zh) * 2013-04-22 2013-07-17 南京农业大学 氟苯尼考注射用原位凝胶及其制备方法

Also Published As

Publication number Publication date
BR112021004192A2 (pt) 2021-05-25
PE20211334A1 (es) 2021-07-22
CO2021004131A2 (es) 2021-07-30
PH12021550477A1 (en) 2021-11-22
KR20210099553A (ko) 2021-08-12
US20210315803A1 (en) 2021-10-14
CA3111385A1 (en) 2020-03-12
CL2021000536A1 (es) 2021-08-20
EP3846781A1 (en) 2021-07-14
WO2020049570A1 (en) 2020-03-12
CN113412109A (zh) 2021-09-17
JP2021536485A (ja) 2021-12-27
MX2021002492A (es) 2021-09-08

Similar Documents

Publication Publication Date Title
BR112016006182A2 (pt) formulações de espiro?isoxazolina de longa duração
CY1120583T1 (el) Σκευασματα ινσουλινης για γρηγορη προσληψη
CR20140541A (es) Formulaciones farmacéuticas tópicas no acuosas
AR104212A1 (es) Formulaciones inyectables de liberación extendida que comprenden un agente activo de isoxazolina, métodos y usos de las mismas
NZ611476A (en) Topical localized isoxazoline formulation
AR094548A1 (es) Dispersión sólida físicamente estable
CL2014003216A1 (es) Composicion de liberacion sostenida inyectable por via intramuscular, que comprende un farmaco, un copolimero biocompatible a base de acido lactico y acido glicolico, con un peso molecular entre 30 y 46 kda y una viscosidad inherente entre 0,25 y 0,31 dl/g, y dmso como disolvente; kit farmaceutico; y metodo para su elaboracion.
BR112016001544A8 (pt) composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório
BR112018068412A2 (pt) composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral
CO2018008444A2 (es) Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CL2018001910A1 (es) Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CY1125005T1 (el) Συμπλοκα υαλουρονανης με φαρμακευτικως δραστικες ουσιες, μεθοδοι και συνθεσεις
EA201991023A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту
EA202190672A1 (ru) Инъекционный антибиотический состав с замедленным высвобождением
CL2018001913A1 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
BR112022004036A2 (pt) Comprimido mastigável palatável
NZ701697A (en) Stable veterinary anthelmintic formulations
ES2538338T3 (es) Método para la estabilización de S-nitrosoglutatión y composición preparada por el mismo
GT201300182A (es) Metodo para el tratamiento de una infeccion
JP2016503058A5 (ru)
EA201900244A1 (ru) Антибактериальные средства на основе производных ципрофлоксацина
BR112015029260A2 (pt) derivados de tilosina e seu método de preparação
BR112018014544A2 (pt) método para preparar uma composição farmacêutica compreendendo um derivado de quinolina ou sal da mesma
BR112022004836A2 (pt) Processo para preparar um hidrogel super poroso plastificado, uso de um ou mais hidrogéis super porosos plastificados e formulação de dosagem oral
BR112021019876A2 (pt) Inibidores de pde9 para tratar anemia falciforme